Israel and the EU will share information on
drugs more systematically in the future, thanks to a Memorandum of Understanding
that was signed today in Jerusalem between the EU drugs agency (EMCDDA) and the
Israel Anti-Drug Authority (IADA).
The agreement was signed at the Israeli Ministry of Foreign Affairs by EMCDDA
Director Wolfgang Götz and IADA Director-General Yair Geller.
Israel had submitted a formal request for
cooperation with the EMCDDA in 2012. This was given a green light from the
EMCDDA Management Board in December of 2012 for the agency to negotiate the MoU
with IADA. .
This accord, signed for an initial period of
five years and sealing cooperation between the two bodies, will be implemented
through a joint work program to be updated every three years. The work program
will include steps to enhance monitoring and knowledge base on the drugs
situation and responses to it, particularly through harmonizing key indicators
in the areas of supply and demand.
Special attention will be given to the regular
exchange of information on the use of new psychotropic substances, as well as
the technologies employed in their production.
The agreement provides for an exchange of
technical expertise and knowledge between the two bodies, the co-sponsoring of
technical meetings and the pooling of human and financial resources to launch
This cooperation takes place within the
EMCDDA’s mandate for
cooperation with third countries in consultation with its Management Board
and the European Commission. The MoU is based on the 1995
Euro–Mediterranean Agreement and the 2005
EU–Israel Action Plan, the latter establishing the general framework of
EU–Israel bilateral relations.